Outcomes

The available evidence on TB-500 (Thymosin Beta-4) outcomes is extremely limited, with most published research focusing on analytical detection methods rather than clinical efficacy.

Clinical Trial Evidence

One ongoing Phase 1/2 clinical trial (NCT07487363) is investigating TB-500's effects on cardiovascular biomarkers in patients with stable atherosclerotic cardiovascular disease (ASCVD). However, as this study is currently recruiting participants, no outcome data has been published.

Published Research Limitations

The peer-reviewed literature primarily consists of:

Analytical chemistry studies developing methods to detect TB-500 in biological samples for anti-doping purposes
Safety and regulatory reviews of peptide therapies that mention TB-500 but provide limited outcome data

Evidence Strength

The evidence for TB-500's clinical outcomes is currently insufficient. While one review article from 2026 addresses "Safety and Efficacy of Approved and Unapproved Peptide Therapies," the specific outcome measures, effect sizes, and clinical significance for TB-500 are not detailed in the available abstracts.

Knowledge Gaps

Measurable clinical outcomes such as:

Specific biomarker changes
Quantified symptom improvements
Functional assessments
Safety profiles

These remain largely unreported in the current peer-reviewed literature for TB-500.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers before considering any therapeutic interventions.

TB-500 (Thymosin Beta-4)

Member access required